Medical staff prepares an AstraZeneca coronavirus vaccine during preparations at the vaccine center in Ebersberg near Munich, Germany, Monday, March 22, 2021. LONDON —
AstraZeneca's COVID-19 vaccine was first given the nod by the EMA in January 2021. Within weeks, however, concerns grew about the vaccine's safety, when dozens of countries suspended the vaccine's use after unusual but rare blood clots were detected in a small number of immunized people. The EU regulator concluded AstraZeneca's shot didn't raise the overall risk of clots, but doubts remained.
Billions of doses of the AstraZeneca vaccine were distributed to poorer countries through a U.N.-coordinated program, as it was cheaper and easier to produce and distribute. But studies later suggested that the pricier messenger RNA vaccines made by Pfizer-BioNTech and Moderna provided better protection against COVID-19 and its many variants, and most countries switched to those shots.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: globeandmail - 🏆 5. / 92 Lire la suite »
La source: timescolonist - 🏆 15. / 75 Lire la suite »
La source: timescolonist - 🏆 15. / 75 Lire la suite »
La source: YahooFinanceCA - 🏆 47. / 63 Lire la suite »
La source: timescolonist - 🏆 15. / 75 Lire la suite »